Evidence map›Paper›PMID 40927849›Full record

ArticleJournal of internal medicine2025

Oxidized high-density lipoprotein associates with cardiometabolic dysfunction in coronary artery disease and acute coronary syndrome.

Benjamin Sasko, Nikolaos Pagonas, Martin Christ, Jan Wintrich, Oliver Ritter, Christian Ukena, Innas Sultana, Simin Delalat, Ibrahim El-Battrawy, Theodoros Kelesidis and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Benjamin SaskoMedical Department II, Ruhr University Bochum, Marien Hospital Herne, Herne, Germany.ORCID https://orcid.org/0000-0001-8157-9875
Nikolaos PagonasDepartment of Cardiology, University Hospital Ruppin-Brandenburg, Medical School Theodor Fontane, Neuruppin, Germany.
Martin ChristDepartment of Cardiology, Knappschaftskrankenhaus Bottrop, Academic Teaching Hospital, University Duisburg-Essen, Bottrop, Germany.
Jan WintrichMedical Department II, Ruhr University Bochum, Marien Hospital Herne, Herne, Germany.
Oliver RitterUniversity Medical Center Brandenburg an der Havel, Medical School Theodor Fontane, Brandenburg an der Havel, Germany.
Christian UkenaMedical Department II, Ruhr University Bochum, Marien Hospital Herne, Herne, Germany.
Innas SultanaDepartment of Cellular and Translational Physiology, Institute of Physiology, Ruhr University Bochum, Bochum, Germany.
Simin DelalatDepartment of Cellular and Translational Physiology, Institute of Physiology, Ruhr University Bochum, Bochum, Germany.
Ibrahim El-BattrawyDepartment of Cellular and Translational Physiology, Institute of Physiology, Ruhr University Bochum, Bochum, Germany.
Theodoros KelesidisDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Nazha HamdaniDepartment of Cellular and Translational Physiology, Institute of Physiology, Ruhr University Bochum, Bochum, Germany.

Funding

Brandenburg Medical School Theodor FontaneDeutsche Forschungsgemeinschaft HA 7512/2-1Deutsche Forschungsgemeinschaft HA 7512/2-4Else-Kröner-Fresenius foundationEuropean CommissionEuropean Union's Horizon 2020 739593German Heart FoundationHector FoundationMedical Faculty IF-023-22Medical Faculty IF-034-22NIA NIH HHS R43 AG059501NIH HHS R01AG059501Stiftungsfond BIOX
6 · The paper itself

Abstract

backgroundHigh-density lipoprotein (HDL) function, rather than its concentration, plays a crucial role in the development of coronary artery disease (CAD). Diminished HDL antioxidant properties, indicated by elevated oxidized HDL (nHDL

methodsWe assessed HDL function in three groups: 90 CAD patients, 90 healthy controls, and 90 ACS patients. HDL antioxidant function was measured using a validated biochemical assay to quantify oxidized HDL (nHDL

resultsACS patients had nHDL

conclusionHDL CLINICAL

trial registrationDRKS00014037.

Indexed as

Acute Coronary SyndromeCoronary Artery DiseaseLipoproteins, HDLAgedAryldialkylphosphataseBiomarkersCase-Control StudiesFemaleHumansInterleukin-6Lipoproteins, LDLMaleMiddle AgedNitric OxideOxidation-ReductionVascular Cell Adhesion Molecule-1AryldialkylphosphataseBiomarkersInterleukin-6Lipoproteins, HDLLipoproteins, LDLNitric Oxideoxidized low density lipoproteinPON1 protein, humanVascular Cell Adhesion Molecule-1acute coronary syndromecardiometabolic functionHDL functionoxidative stressoxidized HDL

Identifiers

PMID40927849
PMCPMC12522528

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.